SRC and cancer: Most of the drugs highly similar to BR were enriched with anti-cancer drugs (Figure 1C), and their known MoAs included the inhibition of epidermal growth factor receptor, RAF, MAPK/ERK Kinase, SRC, and mTOR signaling pathways (Supplementary Figure S2A).